Sandoz Group AG
SDZ · SIX
Public Market Listing
SDZSIX
Live quotes, historical charts, and market capitalization for Sandoz Group AG are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(9 total)
9Total Assets
9Approved
0Phase 3 / Filed
0Phase 1–2 / Early
17Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Approved | TNF-alphaMonoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasisRheumatoid ArthritisHidradenitis SuppurativaNon-Infectious Uveitis Ulcerative Colitis, Crohn's Disease | |
| Approved | VEGF-AProtein / enzyme therapeutic | Age-Related Macular DegenerationDiabetic Macular Edema | |
| Approved | Beta-2 adrenergic receptorSmall molecule | Asthma | |
BAT1706(Avzivi) | Approved | VEGF-AMonoclonal antibody | Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma |
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular DegenerationDiabetic Macular Edema Wet Age-Related Macular Degeneration | |
| Approved | VEGF-AMonoclonal antibody | Age-Related Macular DegenerationDiabetic Macular Edema | |
| Approved | α4 integrinMonoclonal antibody | Multiple Sclerosis | |
| Approved | IL-12 p40Monoclonal antibody | Inflammatory Bowel DiseasePsoriatic ArthritisPsoriasis Ulcerative Colitis, Crohn's Disease | |
| Approved | Farnesyl pyrophosphate synthase (FPPS)Small molecule | Osteoporosis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $11.1B | — | — | — | report ↗ |